Advancement in protein-based nanocarriers in targeted anticancer therapy

Humans have been threatened by cancer as a major health problem. World demographics predicts a dramatic rise in the number of cancer patients for a variety of cancers by the alarming increase in the population. It is anticipated that by 2025 there will be 420 million. The most prominent cancer is diagnosed with different types of tumors such as breast, colorectal, prostate, and lung cancer. Current treatments approaches including anesthesia, chemotherapy, and radiation therapy have been carried out for years. With increasing research in molecular diagnosis and cancer care, the area of cancer therapy has been significantly altered in recent years. Chemotherapy and immunotherapy have recently brought significant progress in cancer treatment but the toxicity of both of these approaches have restricted the therapeutic efficacy. The development of new approaches for the provision of effective anticancer therapies, which could improve the pharmacokinetic and pharmacodynamic effects of the drug and greatly decrease the side effects. In this regard, protein-based nanomedicines are often interested in cancer care. Protein is vital and well investigated in nanocarriers. It also provides selective dissemination of tumor cells through nanovesicular nanocarrier proteins or viruses such as structures, pharmaceutical conjugates, viral particles, etc. In addition, both animal and plant-based proteins, using diverse preparation methods to produce nanocarriers. Therefore, the present research explores the application of protein-based nanomedicine with a special focus on intracellular opioid abuse capacity for cancer-resistant medicines.